abiraterone has been researched along with Bone Cancer in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 40 (78.43) | 24.3611 |
| 2020's | 11 (21.57) | 2.80 |
| Authors | Studies |
|---|---|
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W | 1 |
| Higa, J; Larsen, C; Savino, S; Scholz, M; Vogelzang, N; Wilenius, K | 1 |
| Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
| Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G | 1 |
| Hu, S; Liu, C; Song, S; Su, H; Wang, B; Xu, X; Ye, D; Zhang, Y; Zhu, Y | 1 |
| Chen, C; Fang, H; Ge, H; He, H; He, L; Wan, Y; Wang, L; Wang, Y; Wu, Y | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Amaravadi, R; Black, TA; Buckingham, TH; Calara-Nielsen, K; Carpenter, EL; Cherkas, Y; Foulk, B; Gross, S; Haas, NB; He, M; Jones, JO; LaRiviere, MJ; Long, Q; Majmundar, KJ; Min, EJ; Pal, SK; Patel, J; Savitch, SL; Smirnov, D; Vaughn, DJ; Wellen, KE; Yee, SS | 1 |
| Amling, CL; Aronson, WJ; Cooperberg, MR; De Hoedt, AM; Freedland, SJ; Howard, LE; Kane, CJ; Klaassen, Z; Polascik, TJ; Terris, MK; Vidal, AC; Zhao, H | 1 |
| Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S | 1 |
| Saad, F; Traboulsi, SL | 1 |
| Grimm, MO; von Rundstedt, FC; Winter, BM | 1 |
| Heidenreich, A; Nilsson, S; Parker, C; Shore, N | 1 |
| Chen, J; Dai, Y; Gao, Q | 1 |
| Bauernhofer, T; Belic, J; Cherkas, Y; Geigl, JB; Gormley, M; Graf, R; Gross, M; Heitzer, E; Li, W; Patel, J; Perakis, S; Smirnov, D; Speicher, MR; Ulz, P; Waldispuehl-Geigl, J | 1 |
| Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I | 1 |
| Bryce, AH; Dorff, TB; Groshen, S; Ji, L; Quinn, DI; Wong, W; Yap, KK | 1 |
| Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M | 1 |
| Dalgleish, AG; Di Palma, S; Fusi, A; Nathan, K; Patel, N; Powell, B | 1 |
| Ashworth, A; Assiotis, I; Attard, G; Barber, LJ; Campbell, J; Chen, L; de Bono, J; Fenwick, K; Fong, P; Gevensleben, H; Hylands, L; Kaye, S; Koh, D; Kozarewa, I; Lord, CJ; Miranda, S; Molife, LR; Olmos, D; Omlin, A; Reid, AH; Riisnaes, R; Sandhu, SK; Tunariu, N; Yap, TA | 1 |
| Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S | 1 |
| Armstrong, AJ; Bitting, RL; Chi, KN; Ellard, SL; Noonan, KL; North, S | 1 |
| Aparicio, AM; Goldkorn, A; Quinn, DI | 1 |
| Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C | 1 |
| Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC | 1 |
| Fizazi, K; Loriot, Y; Massard, C | 1 |
| Amadori, D; Bianchi, E; Burgio, SL; Carretta, E; Conteduca, V; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Rossi, L | 1 |
| Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL | 1 |
| Balk, SP; Jiang, Z; Kantoff, PW; McKay, RR; Melnick, K; Montgomery, B; Smith, SE; Taplin, ME; Voznesensky, O; Werner, L; Wu, JS; Yuan, X; Zukotynski, KA | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Gartrell, BA; Saad, F | 1 |
| Baji, P; Berczi, C; Brodszky, V; Géczi, L; Gulácsi, L; Péntek, M; Rencz, F; Szûcs, M | 1 |
| Gong, CL; Hay, JW | 1 |
| Dahut, WL; Madan, R | 1 |
| Carles, J; de Bono, JS; De Porre, P; de Souza, P; Fizazi, K; Flaig, TW; Griffin, TW; Higano, CS; Kheoh, T; Li, J; Logothetis, CJ; Miller, K; Molina, A; Mulders, PF; Naini, V; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Yu, MK | 1 |
| Beer, TM; Graff, JN | 1 |
| He, L; Li, L; Long, Z | 1 |
| Bíró, K; Géczi, L; Küronya, Z; Németh, H | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Boegemann, M; Eminaga, O; Herrmann, E; Hinkelammert, R; Krabbe, LM; Mikah, P; Papavassilis, P; Schrader, AJ; Semjonow, A | 1 |
| Bezrukov, EA; Kondrashina, AV; Rapoport, LM | 1 |
| Albiges, L; Blesius, A; de La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Aljumaily, R; Mathew, P | 1 |
| Goetz, D | 1 |
| Miller, K | 1 |
| Nelson, PS | 1 |
| Chieffo, N; Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Molina, A; Smith, LA; Titus, M; Troncoso, P; Tsavachidou, D; Tzelepi, V; Wen, S | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Petrányi, Á | 1 |
13 review(s) available for abiraterone and Bone Cancer
| Article | Year |
|---|---|
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review.
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment | 2020 |
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.
Topics: Androstenes; Benzamides; Bibliometrics; Bone Neoplasms; DNA Repair; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Publications; Receptors, Androgen; United Kingdom; United States; United States Food and Drug Administration | 2020 |
The role of bone-targeted therapies for prostate cancer in 2017.
Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
[Radium-223 dichloride in patients with castration-refractory prostate cancer].
Topics: Androstenes; Benzamides; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Denosumab; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment | 2017 |
Current approaches to incorporation of radium-223 in clinical practice.
Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome | 2018 |
Pathologic fracture in patients with metastatic prostate cancer.
Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid | 2014 |
[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2014 |
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid | 2015 |
[Treatment strategies for advanced prostate cancer].
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Denosumab; Drug Administration Schedule; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2015 |
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid | 2016 |
New options for the management of castration-resistant prostate cancer: a case perspective.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
[The treatment of castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cancer Vaccines; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Oligonucleotides, Antisense; Orchiectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; RANK Ligand; Receptors, Vascular Endothelial Growth Factor; Taxoids; Tissue Extracts; Treatment Failure | 2012 |
5 trial(s) available for abiraterone and Bone Cancer
| Article | Year |
|---|---|
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome | 2019 |
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Bone Neoplasms; BRCA2 Protein; Humans; Male; Middle Aged; Mutation; Neoplasm Grading; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms | 2013 |
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biopsy; Bone Neoplasms; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiography, Interventional; Radionuclide Imaging; Radiopharmaceuticals; Surgery, Computer-Assisted; Technetium Tc 99m Medronate | 2014 |
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2015 |
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Bone Marrow; Bone Neoplasms; Castration; Disease-Free Survival; Drug Administration Schedule; Fatigue; Histone Deacetylase Inhibitors; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Prostatic Neoplasms; Receptors, Androgen; Remission Induction; Testosterone; Vascular Diseases; Young Adult | 2012 |
33 other study(ies) available for abiraterone and Bone Cancer
| Article | Year |
|---|---|
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids | 2020 |
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Retrospective Studies; Tissue Extracts | 2020 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Antineoplastic Agents, Hormonal; Bone Neoplasms; Glutamate Carboxypeptidase II; Humans; Lymphatic Metastasis; Male; Middle Aged; Organotechnetium Compounds; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptome | 2021 |
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Topics: Aged; Androstenes; Benzamides; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Veterans | 2021 |
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2021 |
Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Neoplasm Grading; Orchiectomy; Physical Examination; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Testicular Neoplasms; Tomography, X-Ray Computed | 2018 |
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Topics: Androgen Receptor Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; DNA Copy Number Variations; DNA, Neoplasm; Drug Resistance, Neoplasm; Follow-Up Studies; Genomics; Humans; Longitudinal Studies; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2018 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2018 |
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Topics: Androstenes; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Pain Management; Palliative Care; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Time Factors | 2019 |
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Receptor Antagonists; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bone Neoplasms; Cancer Vaccines; Humans; Male; Nitriles; Parotid Neoplasms; Receptors, Androgen; Tosyl Compounds | 2019 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2013 |
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2013 |
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2014 |
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2014 |
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Topics: Androstenes; Asymptomatic Diseases; Bone Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Tissue Extracts | 2014 |
Abiraterone's efficacy confirmed; time to aim higher.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2015 |
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment].
Topics: Androstenes; Bone Neoplasms; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2015 |
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
Topics: Aged; Alkaline Phosphatase; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2016 |
[Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Triptorelin Pamoate | 2016 |
[New drugs in metastatic castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Castration; Denosumab; Epothilones; ErbB Receptors; Furans; Humans; Immunotherapy; Ketones; Male; Orchiectomy; Prostatic Neoplasms; Pyrrolidines; RANK Ligand | 2010 |
Optimal management of bone metastases in prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Male; Prostatic Neoplasms; RANK Ligand; Taxoids; Tissue Extracts | 2011 |
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.
Topics: Androstenes; Androstenols; Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Male; Prostatic Neoplasms; Receptors, Androgen | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |